In melanoma, familial mutations in CDKN2A, RB1, and TERT attenuate senescence, enabling uncontrolled proliferation [309], whereas ERK5 inhibition triggers senescence via LTBP1-mediated TGF-β1 activation, which suppresses tumor growth and enhances immunotherapy response [310]. This evidence concerns the gene CDKN2A and neoplasm.